Kidney-Pancreas Transplants: Is It So Difficult to Start a Program?

Alonso, A.; Fernández, Constantino; Villaverde, P.; García, Raquel; Aguirrezabalaga, J.; Gómez, Manuel; Oliver, Juan A.; Valdés, F

doi:10.1016/j.transproceed.2005.02.004

Cited by 7 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, long-term use has its drawbacks, mainly the risk of recurrent infections and neoplastic disease, as well as necessary close and meticulous medical care. 40 Uterine transplantation would be short term that is 1 to 2 years, thus avoiding this risk. Once the uterus and immunosuppressants are removed, any associated neoplasm risk should theoretically return to baseline.…”

Section: Immunosuppressing the Uterine Graftmentioning

confidence: 99%

Immunology of Uterine Transplantation: A Review

et al. 2012

View full text Add to dashboard Cite

The idea of using organ transplantation to solve quality-of-life issues was first introduced a century ago, with cornea transplants and thrusted before the world again in 1998, following a controversial hand transplant. Uterus transplantation (UTn) has been proposed as another quality-of-life transplant for the cure of permanent uterine factor infertility. In order to proceed in humans, a greater appreciation of the immunological mechanisms that underlie UTn is desirable. Allogeneic UTn (animal model) was first described by 2 studies in 1969. The first and only human UTn, performed in 2000, was an early attempt with limited use of animal model experiments prior to moving onto the human setting. Since then, work using rat, mouse, ovine, goat, and nonhuman primate models has demonstrated that the uterus is a very different but manageable organ immunologically compared to other transplanted organs. Therefore, specifically exploring immunological issues relating to UTn is a valuable and necessary part of the inevitable scientific process leading to successful human UTn.

show abstract

Section: Immunosuppressing the Uterine Graftmentioning

confidence: 99%

Immunology of Uterine Transplantation: A Review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Currently short-term effects have been very positive but chronic rejection is still a major issue and long-term use has its drawbacks. These are mainly related to nonspecific suppression of the host immune system, which may cause any of the following: bacterial and viral infections, nephrotoxicity and neurotoxicity with chronic renal failure, newly diagnosed diabetes mellitus, hyperlipidaemia, leucopoenia, and even cancer [15, 21]. …”

Section: Immunosuppression In Generalmentioning

confidence: 99%

Use of Cyclosporine in Uterine Transplantation

Saso

Logan

Abdallah

et al. 2012

Journal of Transplantation

View full text Add to dashboard Cite

Uterine transplantation has been proposed as a possible solution to absolute uterine factor infertility untreatable by any other option. Since the first human attempt in 2000, various teams have tried to clarify which immunosuppressant would be most suitable for protecting the allogeneic uterine graft while posing a minimal risk to the fetus. Cyclosporine A (CsA) is an immunosuppressant widely used by transplant recipients. It is currently being tested as a potential immunosuppressant to be used during UTn. Its effect on the mother and fetus and its influence upon the graft during pregnancy have been of major concern. We review the role of CsA in UTn and its effect on pregnant transplant recipients and their offspring.

show abstract

“…These drugs abort the activation process of alloreactive T cells and the subsequent T-cell proliferation process responsible for GVHD. The situation of a patient living a lifetime under an umbrella of such regimens is associated with the risk of recurrent infections, especially viral, and requires long-term close and meticulous medical care (123). Given the fact that allografting of reproductive organs is still experimental at this stage, there is lack of data on the use of immunosuppressive therapy for this purpose.…”

Section: Immunosuppression and Reproductionmentioning

confidence: 99%